EurekAlert! -
8 Sep 2017 06:00
(European Society for Medical Oncology) Adding taselisib to letrozole before surgery significantly improved outcomes for patients with early breast cancer that was both estrogen receptor positive and HER2-negative (ER+/HER2-) according to results of the LORELEI trial, presented at the ESMO 2017 Congress in Madrid.
Share this Article